SEARCH EISAI MEDICAL INFORMATION:

Product name*
HALAVEN® (eribulin mesylate)
LENVIMA® (lenvatinib)
Lenvima® (lenvatinib)-based therapies*
LENVIMA® (lenvatinib)
LENVIMA® (lenvatinib) + pembrolizumab
LENVIMA® (lenvatinib) + everolimus

*required fields

Please do not include these characters in your search (,),*,-

Please verify spelling of your keywords before submitting

Please provide an input in all required fields

Loading results ....
Please provide an input in all required fields

Please refine your search criteria or submit a medical inquiry.

Please note that LENVIMA is approved only for those indications and dosages that appear in the LENVIMA Full Prescribing Information. The information below and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of LENVIMA that have not been approved by the Food and Drug Administration.

The information below is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding the use of Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Adverse reactions, some of which can be serious or fatal, may occur with LENVIMA, including hypertension, cardiac dysfunction, arterial thromboembolic events, hepatotoxicity, renal failure or impairment, proteinuria, diarrhea, fistula formation and gastrointestinal perforation, QT interval prolongation, hypocalcemia, reversible posterior leukoencephalopathy syndrome, hemorrhagic events, impairment of thyroid stimulating hormone suppression/thyroid dysfunction, impaired wound healing, osteonecrosis of the jaw, and embryo-fetal toxicity. Click here for Important Safety Information.

INDICATIONS

LENVIMA is indicated:

  • For the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC)
  • In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC)
  • In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy
  • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)
  • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR), as determined by an FDA-approved test, or not microsatellite instability-high (MSI-H), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Please note that HALAVEN is approved for those indications and dosages that appear in the HALAVEN Full Prescribing Information. The information provided below and/or its appendices may summarize publications or guidelines that describe indications or treatment modalities for the use of HALAVEN that have not been approved by the Food and Drug Administration.

The information below is provided by Eisai Inc. and is intended to assist you in forming your own clinical conclusions regarding the use of Eisai products. Eisai Inc. does not recommend or endorse the use of this product in any manner other than as described in the Full Prescribing Information.

Adverse reactions, some of which can be serious or fatal, may occur with HALAVEN, including neutropenia, peripheral neuropathy, embryo-fetal toxicity, and QT Prolongation. Click here for Important Safety Information.

INDICATIONS

HALAVEN is indicated:

  • For the treatment of patients with metastatic breast cancer (mBC) who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
  • For the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational agents/uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval.

Eisai does not recommend or endorse the use of this investigational agent in any manner as it has not been approved by the U.S. Food and Drug Administration. This information discusses investigational agents/uses of an agent in development and is not intended to convey conclusions about efficacy, safety, or appropriate use. There is no guarantee that such agent will successfully complete clinical development or gain health authority approval.

Please refine your search criteria or submit a medical inquiry.

Search result(s) may include information that is not consistent with the product's Full Prescribing Information. Eisai does not recommend uses that are inconsistent with the Full Prescribing Information.


TO REPORT SUSPECTED ADVERSE EVENTS OR PRODUCT COMPLAINTS, PLEASE CALL 1-888-274-2378. YOU MAY ALSO REPORT SUSPECTED ADVERSE EVENTS TO THE FDA BY CALLING 1-800-FDA-1088 OR CLICK HERE